BENEFITS OF METFORMIN USE BY BREAST AND COLORECTAL CANCER PATIENTS WITH TYPE 2 DIABBETES MILLITUS: A CASE-CONTROL STUDY IN JIJEL PROVINCE (ALGERIA)
Abstract views: 144 / PDF downloads: 367Keywords:
Colorectal cancer, Type 2 diabetes mellitus, metformin, tumor markers, survivalAbstract
Colorectal cancer and breast cancer are the most diagnosed cancers in Algeria. Recent studies have indicated that metformin is the first-line therapy treatment for type 2 diabetes mellitus; it may be a potential chemoprevention agent. In order to better understand the effect of metformin use on the prognosis of colorectal cancer and breast cancer in patients with type 2 diabetes mellitus, we focused mainly on the study of the tumor markers carcinoembryonic antigen and carbohydrate antigen 19-3/15-3. In this study, patients diagnosed with both colorectal cancer, breast cancer and diabetes mellitus between 2014 and 2018 were identified. Patients’ clinical characteristics were analyzed for the epidemiological, case-control and survival studies in Jijel Province. We found that colorectal cancer placed in 2nd position of all cancers studied (24%), preceded by breast cancer (64%). Colorectal cancer is the most widespread cancer among digestive cancers. There was a significant decrease in serum levels of the tumor markers among the patients treated with metformin. The survival analysis for metformin users revealed that most colorectal cancer cases have been diagnosed under the age of 65 years with a female predominance. Drug combination with metformin (chemotherapy) may enhance a chemopreventive effect during the treatment of colorectal cancer and breast cancer in clinical practice. Metformin users seem to have a decreased serum carbohydrate antigen 19-3/15-3 and carcinoembryonic antigen levels compared with metformin non-users.
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. (2018): Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 68: 394-424.
Mansour, F., Mekhancha, D. E., Kadi, H., Yagoubi-Benatallah, L., Karoune, R., Colette-Dahel-Mekhancha, C., et al. (2018): Malnutrition in patients with breast cancer during treatments (Algeria, 2016). Nutrition Clinique et Metabolism 32: 129-37.
GLOBOCAN. (2019): The Global Cancer Observatory; 2018. gco.iarc.fr/today/fact-sheets-populations. Accessed February 23, 2019.
Abbes, A., Rechreche, H., Brinet, R., Boulkhiout, S., Souilah, N., Benali, M. (2018): Retrospective study of epidemiological, clinicopathological and biological profiles of 62 colorectal cancers cases in Jijel Provence (Algeria). Journal of Fundamental and Applied Sciences 10: 59-82.
Buccafusca, G., Proserpio, I., Tralongo, A. C., Giuliano, S. R., Tralongo, P. (2019): Early colorectal cancer: diagnosis, treatment and survivorship care. Critical Reviews in Oncology/ Hematology 136: 20-30.
Meng, F., Song, L., Wang, W. (2017): Metformin improves overall survival of colorectal cancer patients with diabetes: a meta-analysis. Journal of Diabetes Research Vol. 2017.
Xu, L., Li, Y., Dai, Y., Peng, J. (2018): Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms. Pharmacological Research 130: 451-65.
Forouhi, N. G., Wareham, N. J. (2019): Epidemiology of diabetes. Medicine, 47:22-7.
Luo, S., Li, J. Y., Zhao, L. N., Yu, T., Zhong, W., Xia, Z. S., et al. (2016): Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis. Clinics and Research in Hepatology and Gastroenterology 40: 110-23.
Mills, K. T., Bellows, C. F., Hoffman, A. E., Kelly, T. N., Gagliardi, G. (2013): Diabetes and colorectal cancer prognosis: a meta-analysis. Diseases of the Colon and Rectum 56: 1304.
Rennert, G., Rennert, H. S., Gronich, N., Pinchev, M., Gruber, S. B. (2020): Use of metformin and risk of breast and colorectal cancer. Diabetes Research and Clinical Practice 165: 108232.
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., et al. (2010): Diabetes and cancer: a consensus report. CA: a Cancer Journal for Clinicians 60: 207-21.
Buysschaert, M., Djrolo, F., Guenou, A., Abodo, J., Lokrou, A., Preumont, V., et al. (2016): La metformine revisitée et consolidée en 2016: un point de vue consensuel de l’Afrique à l’Europe. Médecine des Maladies Métaboliques 10: 151-4.
Gallagher, E. J., LeRoith, D. (2011): Minireview: IGF, insulin, and cancer. Endocrinology 152: 2546-51.
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., Vancurova, I. (2018): Metformin as an anticancer agent. Trends in Pharmacological Sciences 39: 867-78.
Faillie, J. L., Bringer, J. (2014): Le risque de cancer associé aux médicaments du diabète de type 2 (metformine, sulfonylurées et insulines). Médecine des Maladies Métaboliques 8: 365-71.
Liu, F., Yan, L., Wang, Z., Lu, Y., Chu, Y., Li, X., et al. (2017): Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget 8: 16017.
Guo, Q., Liu, Z., Jiang, L., Liu, M., Ma, J., Yang, C., et al. (2016): Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase. Molecular Medicine Reports 13: 2590-6.
Guo, Y., Yu. T., Yang, J., Zhang, T., Zhou, Y., He, F., et al. (2015): Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis. American Journal of Cancer Research 5: 3600.
Chen, X., Li, C., He, T., Mao, J., Li, C., Lyu, J., et al. (2016): Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer Biology & Therapy 17: 507-14.
Faria, J., Negalha, G., Azevedo, A., Martel, F. (2019): Metformin and breast cancer: molecular targets. Journal of Mammary Gland Biology and Neoplasia 24: 111-23.
Althans, A. R., Brady, J.T., Keller, D. S., Stein, S. L., Steele, S. R., Times, M. (2017): Are we catching women in the safety net? Colorectal cancer outcomes by gender at a safety net hospital. The American Journal of Surgery 214: 715-20.
Conti, L., Del Cornò, M., Gessani, S. (2020): Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective. Critical Reviews in Oncology/Hematology 145: 102834.
Zhu, B., Sun, Y., Qi, L., Zhong, R., Miao, X. (2015): Dietary legume consumption reduces risk of colorectal cancer: evidence from a meta-analysis of cohort studies. Scientific Reports 5: 8797.
Khiari, H., Ayoub, H. W. B., Khadhra, H. B., Hsairi, M. (2017): Colorectal Cancer Incidence Trend and Projections in Tunisia (1994-2024). Asian Pacific Journal of Cancer Prevention: APJCP 18: 2733-9.
Moore, K. J., Sussman, D. A., Koru-Sengul, T. (2018): Peer Reviewed: Age-Specific Risk Factors for Advanced Stage Colorectal Cancer, 1981–2013. Preventing Chronic Disease 15: 170274.
Steele, S. R., Park, G. E., Johnson, E. K., Martin, M. J., Stojadinovic, A., Maykel, J. A., et al. (2014): The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Diseases of the Colon & Rectum 57: 303-10.
Wu, C.Y., Lin, J. T. (2015): The changing epidemiology of Asian digestive cancers: from etiologies and incidences to preventive strategies. Best Practice & Research Clinical Gastroenterology 29: 843-53.
Aupérin, A., Hill, C. (2005): Épidémiologie des carcinomes des voies aérodigestives supérieures. Cancer/Radiothérapie 9: 1-7.
Darré, T., Amégbor, K., Napo-Koura, G., Bagny, A., Bouglouga, O., Lawson, A. L., et al. (2014): Profil histo-épidémiologique des cancers colorectaux au Togo. Journal Africain d'Hépato-Gastroentérologie 8: 226-9.
Giordano, S. H. (2018): Breast cancer in men. New England Journal of Medicine 378: 2311-20.
Gucalp, A., Traina, T. A., Eisner, J. R., Parker, J. S., Selitsky, S. R., Park, B. H., et al. (2019): Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment 173: 37-48.
Taghizadeh, A., Pourali. L., Joudi, M., Salehi, M., Eshghi, S., Torabian, F., et al. (2019): Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer. Middle East Journal of Cancer 10: 17-22.
Hills, A. P., Arena, R., Khunti, K., Yajnik, C. S., Jayawardena, R., Henry, C. J., et al. (2018): Epidemiology and determinants of type 2 diabetes in south Asia. The Lancet Diabetes & Endocrinology 6: 966-78.
Carstensen, B., Read, S.H., Friis, S., Sund, R., Keskimäki, I., Svensson, A. M., et al. (2016): Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59: 980-8.
Yoon, Y. S., Keum, N., Zhang, X., Cho, E., Giovannucci, E. L. (2015): Hyperinsulinemia, insulin resistance and colorectal adenomas: A meta-analysis. Metabolism, 64: 1324-33.
Simon, D., Balkau, B. (2018): Diabetes mellitus, hyperglycaemia and cancer. Diabetes & Metabolism 36: 182-91.
Amaral, I., Silva, C., Correia-Branco, A., Martel, F. (2018): Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells. Biomedicine & Pharmacotherapy 102: 94-101.
Chae, Y. K., Arya, A., Malecek, M. K., Shin, D.S., Carneiro, B., Chandra, S., et al. (2016): Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7: 40767.
Geng, B., Liang, M. M., Ye, X. B., Zhao, W. Y. (2014): Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology 3: 232-6.
Li, J., Liu, L., Feng, Z., Wang, X., Huang, Y., Dai, H., et al. (2009): Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer 27: 621-30.
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., et al. (2009): Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-15.
Stiksma, J., Grootendorst, D. C., van der Linden, P. W. (2014): G. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. Clinical Colorectal Cancer 13: 239-44.
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., et al. (2003): Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. European Journal of Cancer 39: 718-27.
Sarivalasis, A., Amram, M. L., Dietrich, P. Y. (2013): Marqueurs tumoraux: quelle utilité en pratique clinique? Rev Med Suisse 9: 1102-7.
Hou, Y. C., Hu, Q., Huang, J., Fang, J. Y., Xiong H. (2016): Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. Oncotarget 8: 8843-53.
Peng, M., Darko, K. O., Tao, T., Huang, Y., Su, Q., He, C., et al. (2017): Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer treatment review Treatment Reviews 54: 24-33.
Honjo, S., Ajani, J. A., Scott, A. W., Chen, Q., Skinner, H. D., Stroehlein, J., et al. (2014): Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. International Journal of Oncology 45: 567-74.
Tian, Y., Tang, B., Wang, C., Sun, D., Zhang, R., Luo, N., et al. (2016): Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget 7: 46230-41.
Kanadiya, M. K., Gohel, T. D., Sanaka, M. R., Thota, P. N., Shubrook Jr, J. H. (2013): Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. Journal of Diabetes and its Complications 27: 463-6.
Deng, M., Lei, S., Huang, D., Wang, H., Xia, S., Xu, E., et al. (2019): Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. Pathology-Research and Practice 216: 152775.
Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K., et al. (2012): Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 107: 1608-17.
Michels, K. B., Solomon, C. G., Hu, F. B., Rosner, B. A., Hankinson, S. E., Colditz, G. A., et al. (2003): Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 26: 1752-8.
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., et al. (2018): Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysis. Cancer Epidemiology and Prevention Biomarkers 27: 627-35.
Duffy, M. J., Evoy, D., McDermott, E. W. (2010): CA 15-3: uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta 411:1869-74.
Pizzuti, L., Vici, P., Di Lauro, L., Sergi, D., Della Giulia, M., Marchetti, P., et al. (2015): Metformin and breast cancer: basic knowledge in clinical context. Cancer Treatment Reviews 41: 441-7.
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C., et al. (2009): Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology 27: 3297-302.
Campbell, P. T., Deka, A., Jacobs, E. J., Newton, C. C., Hildebrand, J. S., McCullough, M. L., et al. (2010): Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 139:1138-46.
Ma, Y., Yang, W., Song, M., Smith-Warner, S. A., Yang, J., Li, Y., et al. (2018): Type 2 diabetes and risk of colorectal cancer in two large US prospective cohorts. British Journal of Cancer 119:1436-42.
Garrett, C. R., Hassabo, H. M., Bhadkamkar, N. A., Wen, S., Baladandayuthapani, V., Kee, B. K., et al. (2012): Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. British Journal of Cancer 106:1374-8.
Lee, J. H., Kim, T. I., Jeon, S. M., Hong, S. P., Cheon, J. H., Kim, W. H. (2012): The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. International Journal of Cancer 131:752-9.
Paulus, J. K., Williams, C. D., Cossor, F., I., Kelley, M. J., Martell, R. E. (2016): Metformin, diabetes, and survival among US veterans with colorectal cancer. Cancer Epidemiology and Prevention Biomarkers 25:1418-25.
Richardson, L. C., Pollack, L. A. (2005): Perspective thérapeutique: influence du diabète de type 2 sur le développement, le traitement et les résultats du cancer. Nature Clinical Practice Oncology, 2:48-53.
Kasznicki, J., Sliwinska, A., Drzewoski, J. (2014): Metformin in cancer prevention and therapy. Annals of Translational Medicine 2:57.
Duan, W., Shen, X., Lei, J., Xu, Q., Yu, Y., Li, R., et al. (2014): Hyperglycemia, a neglected factor during cancer progression. BioMed Research International 2014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Applied Biological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
JABS is licensed under a 